Experience

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Silicon Laboratories Inc. of $400 million aggregate principal amount of its…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised SS&C Technologies Holdings, Inc. on its acquisition of Conifer Financial Services, LLC for an aggregate purchase price of $88.5 million, subject to customary…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $2.85 billion aggregate principal amount of 2.350% notes due 2019, $2.85 billion…

Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…

Davis Polk advised Shire plc on the $12.1 billion SEC-registered debt offering by its wholly owned subsidiary, Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), consisting of $3.3…

Davis Polk advised NBCUniversal Media, LLC, on behalf of Comcast Corporation, in connection with its acquisition of SportsEngine, an industry-leading sports technology platform in the youth…

Davis Polk advised the representative of the underwriters in connection with the $181 million public offering of 4,025,000 shares of common stock of Spark Therapeutics, Inc. (“Spark”),…

Davis Polk is advising Solvay SA in connection with its acquisition of the remaining 50% interest in Primester, a joint venture partnership between Solvay and Eastman Chemical Company…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…